Catalyst Pharma Holds 2025 Annual Stockholders Meeting

Catalyst Pharma ( (CPRX) ) has shared an update.

At Catalyst Pharma‘s 2025 Annual Meeting of Stockholders on May 20, 2025, several directors were elected to the Board, including Richard J. Daly, Patrick J. McEnany, Donald A. Denkhaus, Molly Harper, Tamar Thompson, and David S. Tierney, to serve until the 2026 meeting. Charles B. O’Keeffe, a long-standing independent board member, retired without any disagreements with the company. Additionally, the meeting saw the approval of an amendment to the 2018 Stock Incentive Plan, the 2024 executive compensation, and the ratification of Grant Thornton, LLP as the independent accounting firm for 2025.

The most recent analyst rating on (CPRX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance, highlighted by robust revenue growth and high margins, is a major strength. The technical indicators suggest stable market sentiment with potential for growth. The valuation is reasonable, though the absence of a dividend yield is a consideration for some investors. Overall, the company is well-positioned for future growth, but investors should be mindful of potential challenges such as cash flow volatility and generic competition for FYCOMPA.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Average Trading Volume: 1,302,895

Technical Sentiment Signal: Buy

Current Market Cap: $2.94B

See more insights into CPRX stock on TipRanks’ Stock Analysis page.